
Anette E Schrag

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7120106/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Vitamin D levels in children and adolescents with chronic tic disorders: a multicentre study. European Child and Adolescent Psychiatry, 2022, 31, 1-12.	4.7	12
2	Clinical precursors of tics: an EMTICS study. Journal of Child Psychology and Psychiatry and Allied Disciplines, 2022, 63, 305-314.	5.2	15
3	Rate of Hospitalizations and Underlying Reasons Among People with Parkinson's Disease: Population-Based Cohort Study in UK Primary Care. Journal of Parkinson's Disease, 2022, 12, 411-420.	2.8	8
4	Identification of Prodromal Presentations of Parkinson's Disease among Primary Care Outpatients in Germany. Neuroepidemiology, 2022, 56, 41-49.	2.3	6
5	The neuropsychiatry of Parkinson's disease: advances and challenges. Lancet Neurology, The, 2022, 21, 89-102.	10.2	142
6	Systematic review and meta-analysis of clinical effectiveness of self-management interventions in Parkinson's disease. BMC Geriatrics, 2022, 22, 45.	2.7	18
7	Caregiver Burden and Quality of Life in Late Stage Parkinson's Disease. Brain Sciences, 2022, 12, 111.	2.3	13
8	Developing and assessing a new web-based tapping test for measuring distal movement in Parkinson's disease: a Distal Finger Tapping test. Scientific Reports, 2022, 12, 386.	3.3	22
9	Change in the incidence of Parkinson's disease in a large UK primary care database. Npj Parkinson's Disease, 2022, 8, 23.	5.3	12
10	Pre-diagnostic presentations of Multiple System Atrophy case control study in a primary care dataset. Parkinsonism and Related Disorders, 2022, 99, 101-104.	2.2	10
11	Assessment of Risk Factors and Early Presentations of Parkinson Disease in Primary Care in a Diverse UK Population. JAMA Neurology, 2022, 79, 359.	9.0	25
12	The Cost Effectiveness of Levodopa-Carbidopa Intestinal Gel in the Treatment of Advanced Parkinson's Disease in England. Pharmacoeconomics, 2022, 40, 559-574.	3.3	5
13	Orthostatic Hypotension and Antiparkinsonian Drugs: A Systematic Review and Meta-analysis. Journal of Geriatric Psychiatry and Neurology, 2022, 35, 639-654.	2.3	7
14	Confidence College – an online education tool for neurology patients. Advances in Clinical Neuroscience & Rehabilitation: ACNR, 2022, 21, 6-9.	0.1	0
15	Exploring the experiences of people and family carers from under-represented groups in self-managing Parkinson's disease and their use of digital health to do this. Digital Health, 2022, 8, 205520762211022.	1.8	4
16	Lower lymphocyte count is associated with increased risk of Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, A94.3-A95.	1.9	0
17	249†Slow motion analysis of repetitive tapping (SMART) test: a new measurement of bradykinesia. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, A85.2-A85.	1.9	0
18	Parkinson's disease determinants, prediction and gene-environment interac- tions: a UK Biobank study. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, A7.3-A8.	1.9	0

#	Article	IF	CITATIONS
19	228†Testing shortened versions of smell tests to screen for hyposmia in Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, A79.2-A79.	1.9	0
20	Abbreviated MDS-UPDRS for Remote Monitoring in PD Identified Using Exhaustive Computational Search. Parkinson's Disease, 2022, 2022, 1-7.	1.1	4
21	The effectiveness of aromatherapy and reflexology in neurodegenerative disorders: a systematic review and meta-analysis. Neurodegenerative Disease Management, 2022, 12, 253-265.	2.2	1
22	Transitions and challenges for people with Parkinson's and their family members: A qualitative study. PLoS ONE, 2022, 17, e0268588.	2.5	4
23	Characterization of Nonâ€Motor Fluctuations Using the Movement Disorder Society <scp>Nonâ€Motor</scp> Rating Scale. Movement Disorders Clinical Practice, 2022, 9, 932-940.	1.5	5
24	Assessment of Ataxia Rating Scales and Cerebellar Functional Tests: Critique and Recommendations. Movement Disorders, 2021, 36, 283-297.	3.9	52
25	Prevalence of Nonâ€Motor Symptoms and Nonâ€Motor Fluctuations in Parkinson's Disease Using the <scp>MDSâ€NMS</scp> . Movement Disorders Clinical Practice, 2021, 8, 231-239.	1.5	35
26	Late onset depression: dopaminergic deficit and clinical features of prodromal Parkinson's disease: a cross-sectional study. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 158-164.	1.9	29
27	Clinical Non-Motor Phenotyping of Black and Asian Minority Ethnic Compared to White Individuals with Parkinson's Disease Living in the United Kingdom. Journal of Parkinson's Disease, 2021, 11, 299-307.	2.8	15
28	Characteristics of Patients with Late-Stage Parkinsonism Who are Nursing Home Residents Compared with those Living at Home. Journal of the American Medical Directors Association, 2021, 22, 440-445.e2.	2.5	18
29	The Nonâ€Motor Symptoms Scale in Parkinson's disease: Validation and use. Acta Neurologica Scandinavica, 2021, 143, 3-12.	2.1	49
30	The motor prodromes of parkinson's disease: from bedside observation to large-scale application. Journal of Neurology, 2021, 268, 2099-2108.	3.6	27
31	Lower Lymphocyte Count is Associated With Increased Risk of Parkinson's Disease. Annals of Neurology, 2021, 89, 803-812.	5.3	38
32	Association of Group A <i>Streptococcus</i> Exposure and Exacerbations of Chronic Tic Disorders. Neurology, 2021, 96, e1680-e1693.	1.1	30
33	Sequence of clinical and neurodegeneration events in Parkinson's disease progression. Brain, 2021, 144, 975-988.	7.6	49
34	Resource Utilization of Patients with Parkinson's Disease in the Late Stages of the Disease in Germany: Data from the CLaSP Study. Pharmacoeconomics, 2021, 39, 601-615.	3.3	11
35	Perspectives on Care for Late-Stage Parkinson's Disease. Parkinson's Disease, 2021, 2021, 1-11.	1.1	13
36	Factors Associated with Healthâ€Related Quality of Life in Lateâ€&tage Parkinson's Disease. Movement Disorders Clinical Practice, 2021, 8, 563-570.	1.5	16

#	Article	IF	CITATIONS
37	Improving estimation of Parkinson's disease risk—the enhanced PREDICT-PD algorithm. Npj Parkinson's Disease, 2021, 7, 33.	5.3	13
38	Slow Motion Analysis of Repetitive Tapping (SMART) Test: Measuring Bradykinesia in Recently Diagnosed Parkinson's Disease and Idiopathic Anosmia. Journal of Parkinson's Disease, 2021, 11, 1901-1915.	2.8	6
39	Mortality of People with Parkinson's Disease in a Large <scp>UK</scp> â€Based Cohort Study: Time Trends and Relationship to Disease Duration. Movement Disorders, 2021, 36, 2811-2820.	3.9	8
40	Digital health technology for non-motor symptoms in people with Parkinson's disease: Futile or future?. Parkinsonism and Related Disorders, 2021, 89, 186-194.	2.2	26
41	Advance Care Planning and Care Coordination for People With Parkinson's Disease and Their Family Caregivers—Study Protocol for a Multicentre, Randomized Controlled Trial. Frontiers in Neurology, 2021, 12, 673893.	2.4	7
42	Mild Parkinsonian Signs: A Systematic Review of Clinical, Imaging, and Pathological Associations. Movement Disorders, 2021, 36, 2481-2493.	3.9	15
43	Optimising classification of Parkinson's disease based on motor, olfactory, neuropsychiatric and sleep features. Npj Parkinson's Disease, 2021, 7, 87.	5.3	4
44	Mycoplasma pneumoniae IgG positivity is associated with tic severity in chronic tic disorders. Brain, Behavior, and Immunity, 2021, 99, 281-288.	4.1	6
45	Identifying Parkinson's disease subtypes with motor and non-motor symptoms via model-based multi-partition clustering. Scientific Reports, 2021, 11, 23645.	3.3	11
46	Health care professionals' perspectives on self-management for people with Parkinson's: qualitative findings from a UK study. BMC Geriatrics, 2021, 21, 706.	2.7	14
47	The Movement Disorder Society Nonmotor Rating Scale: Initial Validation Study. Movement Disorders, 2020, 35, 116-133.	3.9	59
48	Parkinson's disease determinants, prediction and gene–environment interactions in the UK Biobank. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 1046-1054.	1.9	59
49	Self-Management Components as Experienced by People with Parkinson's Disease and Their Carers: A Systematic Review and Synthesis of the Qualitative Literature. Parkinson's Disease, 2020, 2020, 1-10.	1.1	18
50	What contributes to quality of life in Parkinson's disease: a re-evaluation. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 563-565.	1.9	6
51	Application of a Simple Parkinson's Disease Risk Score in a Longitudinal <scp>Populationâ€Based</scp> Cohort. Movement Disorders, 2020, 35, 1658-1662.	3.9	11
52	Factor Analysis and Clustering of the Movement Disorder Society–Nonâ€Motor Rating Scale. Movement Disorders, 2020, 35, 969-975.	3.9	9
53	Experiences of advance care planning in Parkinson's disease and atypical parkinsonian disorders: a mixed methods systematic review. European Journal of Neurology, 2020, 27, 1971-1987.	3.3	16
54	Antiâ€dopamine D2 receptor antibodies in chronic tic disorders. Developmental Medicine and Child Neurology, 2020, 62, 1205-1212.	2.1	15

#	Article	IF	CITATIONS
55	Brain iron deposition is linked with cognitive severity in Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 418-425.	1.9	121
56	Factors associated with hospitalisation among people with Parkinson's disease – A systematic review and meta-analysis. Parkinsonism and Related Disorders, 2020, 71, 66-72.	2.2	51
57	Impulse control and related behaviors in Parkinson's disease with dementia. European Journal of Neurology, 2020, 27, 944-950.	3.3	15
58	The Prevalence and Determinants of Neuropsychiatric Symptoms in <scp>Lateâ€Stage</scp> Parkinsonism. Movement Disorders Clinical Practice, 2020, 7, 531-542.	1.5	24
59	Testing Shortened Versions of Smell Tests to Screen for Hyposmia in Parkinson's Disease. Movement Disorders Clinical Practice, 2020, 7, 394-398.	1.5	11
60	Visual tests predict dementia risk in Parkinson disease. Neurology: Clinical Practice, 2020, 10, 29-39.	1.6	41
61	The late stage of Parkinson's –results of a large multinational study on motor and non-motor complications. Parkinsonism and Related Disorders, 2020, 75, 91-96.	2.2	25
62	European Multicentre Tics in Children Studies (EMTICS): protocol for two cohort studies to assess risk factors for tic onset and exacerbation in children and adolescents. European Child and Adolescent Psychiatry, 2019, 28, 91-109.	4.7	36
63	Antibodies to neuronal surface proteins in Tourette Syndrome: Lack of evidence in a European paediatric cohort. Brain, Behavior, and Immunity, 2019, 81, 665-669.	4.1	15
64	Non-motor outcomes depend on location of neurostimulation in Parkinson's disease. Brain, 2019, 142, 3592-3604.	7.6	90
65	Pilot Study of the International Parkinson and Movement Disorder Societyâ€sponsored Nonâ€motor Rating Scale (MDSâ€NMS). Movement Disorders Clinical Practice, 2019, 6, 227-234.	1.5	31
66	Scales to assess impulsive and compulsive behaviors in Parkinson's disease: Critique and recommendations. Movement Disorders, 2019, 34, 791-798.	3.9	49
67	Neuropsychiatric aspects of Parkinson's disease. Journal of Neural Transmission, 2019, 126, 889-896.	2.8	25
68	Using global team science to identify genetic parkinson's disease worldwide. Annals of Neurology, 2019, 86, 153-157.	5.3	26
69	Screening performance of abbreviated versions of the UPSIT smell test. Journal of Neurology, 2019, 266, 1897-1906.	3.6	37
70	Heterogeneity in progression of prodromal features in Parkinson's disease. Parkinsonism and Related Disorders, 2019, 64, 275-279.	2.2	15
71	Dyskinesia in multiple system atrophy and progressive supranuclear palsy. Journal of Neural Transmission, 2019, 126, 925-932.	2.8	11
72	Predicting diagnosis of Parkinson's disease: A risk algorithm based on primary care presentations. Movement Disorders, 2019, 34, 480-486.	3.9	69

#	Article	IF	CITATIONS
73	Experiences of health services and unmet care needs of people with late-stage Parkinson's in England: A qualitative study. PLoS ONE, 2019, 14, e0226916.	2.5	26
74	Report from a multidisciplinary meeting on anxiety as a non-motor manifestation of Parkinson's disease. Npj Parkinson's Disease, 2019, 5, 30.	5.3	32
75	The prodromes of Parkinson's disease. European Journal of Neuroscience, 2019, 49, 320-327.	2.6	30
76	Assessing cognitive dysfunction in Parkinson's disease: An online tool to detect visuoâ€perceptual deficits. Movement Disorders, 2018, 33, 544-553.	3.9	25
77	Short―and longâ€ŧerm cost and utilization of health care resources in Parkinson's disease in the UK. Movement Disorders, 2018, 33, 974-981.	3.9	53
78	Dopamine reuptake transporter–singleâ€photon emission computed tomography and transcranial sonography as imaging markers of prediagnostic Parkinson's disease. Movement Disorders, 2018, 33, 478-482.	3.9	25
79	Clinical Rating Scales for Urinary Symptoms in Parkinson Disease: Critique and Recommendations. Movement Disorders Clinical Practice, 2018, 5, 479-491.	1.5	18
80	Relationship between the MDS-UPDRS and Quality of Life: A large multicenter study of 3206 patients. Parkinsonism and Related Disorders, 2018, 52, 83-89.	2.2	46
81	Patient experiences of receiving a diagnosis of Parkinson's disease. Journal of Neurology, 2018, 265, 1151-1157.	3.6	21
82	Mild Cognitive Impairment in Parkinson's Disease—What Is It?. Current Neurology and Neuroscience Reports, 2018, 18, 17.	4.2	57
83	Dietary Variations in a Multiethnic Parkinson's Disease Cohort and Possible Influences on Nonmotor Aspects: A Cross-Sectional Multicentre Study. Parkinson's Disease, 2018, 2018, 1-9.	1.1	4
84	Study protocol: Care of Late-Stage Parkinsonism (CLaSP): a longitudinal cohort study. BMC Neurology, 2018, 18, 185.	1.8	27
85	Development and clinimetric assessment of a nurse-administered screening tool for movement disorders in psychosis. BJPsych Open, 2018, 4, 404-410.	0.7	3
86	An early diagnosis is not the same as a timely diagnosis of Parkinson's disease. F1000Research, 2018, 7, 1106.	1.6	30
87	Testing the <scp>MDS</scp> clinical diagnostic criteria for Parkinson's disease. Movement Disorders, 2018, 33, 1518-1520.	3.9	4
88	Experience of care for Parkinson's disease in European countries: a survey by the European Parkinson's Disease Association. European Journal of Neurology, 2018, 25, 1410.	3.3	21
89	Can neuroimaging predict dementia in Parkinson's disease?. Brain, 2018, 141, 2545-2560.	7.6	46
90	The subjective experience of Parkinson's disease: A qualitative study in 60 people with mild to moderate Parkinson's in 11 European countries. European Journal for Person Centered Healthcare, 2018, 6, 447.	0.3	6

#	Article	IF	CITATIONS
91	PREDICT-PD: An online approach to prospectively identify risk indicators of Parkinson's disease. Movement Disorders, 2017, 32, 219-226.	3.9	59
92	Differences in <scp>MDS</scp> â€ <scp>UPDRS</scp> Scores Based on Hoehn and Yahr Stage and Disease Duration. Movement Disorders Clinical Practice, 2017, 4, 536-544.	1.5	65
93	Rasch analysis of the carers quality of life questionnaire for parkinsonism. Movement Disorders, 2017, 32, 463-466.	3.9	3
94	Subtle motor disturbances in PREDICT-PD participants. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 212-217.	1.9	19
95	Cognitive decline before diagnosis of Parkinson's disease – Authors' reply. Lancet Neurology, The, 2017, 16, 262.	10.2	2
96	Viral hepatitis and Parkinson disease. Neurology, 2017, 88, 1630-1633.	1.1	47
97	The Catsâ€andâ€Dogs test: A tool to identify visuoperceptual deficits in Parkinson's disease. Movement Disorders, 2017, 32, 1789-1790.	3.9	26
98	Non-Motor Symptoms Assessed by Non-Motor Symptoms Questionnaire and Non-Motor Symptoms Scale in Parkinson's Disease in Selected Asian Populations. Neuroepidemiology, 2017, 49, 1-17.	2.3	29
99	Reply: MRI findings of visual system alterations in Parkinson's disease. Brain, 2017, 140, e70-e70.	7.6	0
100	Depression and Anxiety in Parkinson's Disease. International Review of Neurobiology, 2017, 133, 623-655.	2.0	107
101	Study protocol: Insight 46 – a neuroscience sub-study of the MRC National Survey of Health and Development. BMC Neurology, 2017, 17, 75.	1.8	64
102	Clinical variables and biomarkers in prediction of cognitive impairment in patients with newly diagnosed Parkinson's disease: a cohort study. Lancet Neurology, The, 2017, 16, 66-75.	10.2	304
103	Current concepts and controversies in the pathogenesis of Parkinson's disease dementia and Dementia with Lewy Bodies. F1000Research, 2017, 6, 1604.	1.6	35
104	Estimating the causal influence of body mass index on risk of Parkinson disease: A Mendelian randomisation study. PLoS Medicine, 2017, 14, e1002314.	8.4	152
105	Disability Rating Scales in Parkinson's Disease: Critique and Recommendations. Movement Disorders, 2016, 31, 1455-1465.	3.9	87
106	Measurement instruments to assess posture, gait, and balance in Parkinson's disease: Critique and recommendations. Movement Disorders, 2016, 31, 1342-1355.	3.9	212
107	Healthcare Resource Utilisation And Cost Of Parkinson's Disease In The United Kingdom. Value in Health, 2016, 19, A428-A429.	0.3	1
108	Rating Scales for Pain in Parkinson's Disease: Critique and Recommendations. Movement Disorders Clinical Practice, 2016, 3, 527-537.	1.5	46

#	Article	IF	CITATIONS
109	Serotonergic loss underlying apathy in Parkinson's disease. Brain, 2016, 139, 2338-2339.	7.6	9
110	Visual dysfunction in Parkinson's disease. Brain, 2016, 139, 2827-2843.	7.6	320
111	Accuracy of screening instruments for detection of neuropsychiatric syndromes in Parkinson's disease. Movement Disorders, 2016, 31, 270-279.	3.9	55
112	Challenges of modifying disease progression in prediagnostic Parkinson's disease. Lancet Neurology, The, 2016, 15, 637-648.	10.2	78
113	Development and validation of a carers quality-of-life questionnaire for parkinsonism (PQoL Carers). Quality of Life Research, 2016, 25, 81-88.	3.1	20
114	Constipation preceding Parkinson's disease: a systematic review and meta-analysis. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 710-716.	1.9	152
115	New clinical trials for nonmotor manifestations of Parkinson's disease. Movement Disorders, 2015, 30, 1490-1504.	3.9	81
116	Why do patients with Parkinson's disease fall? A cross-sectional analysis of possible causes of falls. Npj Parkinson's Disease, 2015, 1, 15011.	5.3	44
117	Webâ€based assessment of Parkinson's prodromal markers identifies GBA variants. Movement Disorders, 2015, 30, 1002-1003.	3.9	6
118	A new scale for the assessment of pain in Parkinson's disease. Movement Disorders, 2015, 30, 1589-1590.	3.9	0
119	Scales to Assess Clinical Features of Progressive Supranuclear Palsy: MDS Task Force Report. Movement Disorders Clinical Practice, 2015, 2, 127-134.	1.5	20
120	CONSTIPATION PRECEDING PARKINSON'S DISEASE–META-ANALYSIS. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, e4.193-e4.	1.9	5
121	Prediagnostic presentations of Parkinson's disease in primary care: a case-control study. Lancet Neurology, The, 2015, 14, 57-64.	10.2	487
122	Psychosis in Parkinson's Disease. Neuropsychiatric Symptoms of Neurological Disease, 2015, , 113-139.	0.3	1
123	Assessment of Parkinson's disease levodopa-induced dyskinesia: a qualitative research study. Quality of Life Research, 2015, 24, 1899-1910.	3.1	2
124	PREDICT-PD: Identifying risk of Parkinson's disease in the community: methods and baseline results. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 31-37.	1.9	90
125	Genetic comorbidities in Parkinson's disease. Human Molecular Genetics, 2014, 23, 831-841.	2.9	57
126	Measurement of costs and scales for outcome evaluation in health economic studies of Parkinson's disease. Movement Disorders, 2014, 29, 169-176.	3.9	15

#	Article	IF	CITATIONS
127	Review of Quality of Life Instruments for the Restless Legs Syndrome/Willis-Ekbom Disease (RLS/WED): Critique and Recommendations. Journal of Clinical Sleep Medicine, 2014, 10, 1351-1357.	2.6	25
128	Review of Severity Rating Scales for Restless Legs Syndrome: Critique and Recommendations. Movement Disorders Clinical Practice, 2014, 1, 317-324.	1.5	32
129	Review of Diagnostic Instruments for the Restless Legs Syndrome/Willis-Ekbom Disease (RLS/WED): Critique and Recommendations. Journal of Clinical Sleep Medicine, 2014, 10, 1343-1349.	2.6	47
130	Mapping the EQ-5D index by UPDRS and PDQ-8 in patients with Parkinson's disease. Health and Quality of Life Outcomes, 2013, 11, 35.	2.4	18
131	Dystonia rating scales: Critique and recommendations. Movement Disorders, 2013, 28, 874-883.	3.9	150
132	Time trends in incidence of Parkinson's disease diagnosis in UK primary care. Journal of Neurology, 2013, 260, 1351-1357.	3.6	49
133	Olfactory impairment and pathology in neurodegenerative disorders with brain iron accumulation. Acta Neuropathologica, 2013, 126, 151-153.	7.7	9
134	Imaging Psychogenic Movement Disorders. Current Neurology and Neuroscience Reports, 2013, 13, 402.	4.2	15
135	The natural history of multiple system atrophy: a prospective European cohort study. Lancet Neurology, The, 2013, 12, 264-274.	10.2	426
136	Task force report: Scales for screening and evaluating tremor: Critique and recommendations. Movement Disorders, 2013, 28, 1793-1800.	3.9	124
137	<scp>EFNS</scp> / <scp>MDS</scp> â€< scp>ES recommendations for the diagnosis of <scp>P</scp> arkinson's disease. European Journal of Neurology, 2013, 20, 16-34.	3.3	460
138	Coactivation sign in fixed dystonia. Parkinsonism and Related Disorders, 2013, 19, 474-476.	2.2	8
139	Validation of the French version of the MSA health-related Quality of Life scale (MSA-QoL). Revue Neurologique, 2013, 169, 53-58.	1.5	5
140	The functional neuroimaging correlates of psychogenic versus organic dystonia. Brain, 2013, 136, 770-781.	7.6	83
141	Health-Related Quality of Life in Gilles de la Tourette Syndrome: A Decade of Research. Behavioural Neurology, 2013, 27, 83-93.	2.1	85
142	Health-related quality of life in Gilles de la Tourette syndrome: a decade of research. Behavioural Neurology, 2013, 27, 83-93.	2.1	49
143	024â€What is the clinically relevant change on the ADAS-cog?. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, e1.187-e1.	1.9	82
144	What is the clinically relevant change on the ADAS-Cog?. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 171-173.	1.9	117

#	Article	IF	CITATIONS
145	Kayser–Fleischer Rings in Wilson's Disease. New England Journal of Medicine, 2012, 366, e18.	27.0	4
146	Scales to detect depression in Parkinson disease. Nature Reviews Neurology, 2012, 8, 359-360.	10.1	9
147	120â€An algorithm to identify individuals at high-risk of Parkinson's disease in the community. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, e1.71-e1.	1.9	0
148	119â€A pilot study of an algorithm designed to identify Parkinson's disease in the early, non-motor phase. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, e1.70-e1.	1.9	0
149	Metaâ€analysis of early nonmotor features and risk factors for Parkinson disease. Annals of Neurology, 2012, 72, 893-901.	5.3	607
150	Levodopa-Induced-Dyskinesias Clinical Features, Incidence, Risk Factors, Management and Impact on Quality of Life. Journal of Parkinson's Disease, 2012, 2, 189-198.	2.8	132
151	Joint hypermobility syndrome: A risk factor for fixed dystonia?. Movement Disorders, 2012, 27, 1070-1070.	3.9	12
152	Psychosis, apathy, depression and anxiety in Parkinson's disease. Neurobiology of Disease, 2012, 46, 581-589.	4.4	184
153	Validation of the MDSâ€UPDRS Part I for nonmotor symptoms in Parkinson's disease. Movement Disorders, 2012, 27, 79-83.	3.9	97
154	Psychogenic dystonia. , 2012, , 307-319.		0
155	Apathy and depression scales in Parkinson's disease: Are they good enough?. Journal of the Neurological Sciences, 2011, 310, 216-219.	0.6	16
156	The Role of Cognitive-Behavioural Therapy for Patients with Depression in Parkinson's Disease. Parkinson's Disease, 2011, 2011, 1-8.	1.1	11
157	Adolescent and Adult Children of Parents with Parkinson's Disease: Incorporating Their Needs in Clinical Guidelines. Parkinson's Disease, 2011, 2011, 1-6.	1.1	16
158	Measuring quality of life in progressive supranuclear palsy. , 2011, , 52-59.		1
159	Reply: Neuropsychiatric symptoms in Parkinson's disease. Movement Disorders, 2011, 26, 191-192.	3.9	0
160	The <i>Movement</i> Disorders task force review of dysautonomia rating scales in Parkinson's disease with regard to symptoms of orthostatic hypotension. Movement Disorders, 2011, 26, 1985-1992.	3.9	52
161	Healthâ€related qualityâ€ofâ€ŀife scales in Parkinson's disease: Critique and recommendations. Movement Disorders, 2011, 26, 2371-2380.	3.9	234
162	Wearingâ€off scales in Parkinson's disease: Critique and recommendations. Movement Disorders, 2011, 26, 2169-2175.	3.9	101

#	Article	IF	CITATIONS
163	Hyperkinetic psychogenic movement disorders. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2011, 100, 719-729.	1.8	15
164	Parkinson disease clinical subtypes and their implications. Nature Reviews Neurology, 2011, 7, 247-248.	10.1	16
165	Testing an aetiological model of visual hallucinations in Parkinson's disease. Brain, 2011, 134, 3299-3309.	7.6	132
166	A comparison of depression, anxiety, and health status in patients with progressive supranuclear palsy and multiple system atrophy. Movement Disorders, 2010, 25, 1077-1081.	3.9	106
167	Fatigue rating scales critique and recommendations by the Movement Disorders Society task force on rating scales for Parkinson's disease. Movement Disorders, 2010, 25, 805-822.	3.9	193
168	Task force report on scales to assess dyskinesia in Parkinson's disease: Critique and recommendations. Movement Disorders, 2010, 25, 1131-1142.	3.9	90
169	Scales to assess sleep impairment in Parkinson's disease: Critique and recommendations. Movement Disorders, 2010, 25, 2704-2716.	3.9	214
170	Presentation, diagnosis, and management of multiple system atrophy in Europe: Final analysis of the European multiple system atrophy registry. Movement Disorders, 2010, 25, 2604-2612.	3.9	205
171	What are the most important nonmotor symptoms in patients with Parkinson's disease and are we missing them?. Movement Disorders, 2010, 25, 2493-2500.	3.9	405
172	STREPTOCOCCAL INFECTION, TOURETTE SYNDROME, AND OCD: IS THERE A CONNECTION? PANDAS: HORSE OR ZEBRA?. Neurology, 2010, 74, 1397-1399.	1.1	21
173	Hot-Cross Bun Sign. , 2010, , 26.		0
174	Refinement and validation of the Parental Illness Impact Scale. Parkinsonism and Related Disorders, 2010, 16, 181-185.	2.2	12
175	Health-Related Quality of Life in Movement Disorders. , 2010, , 4013-4034.		3
176	Chapter 6 The management of early Parkinson's disease. , 2010, , .		0
177	Comparative responsiveness of Parkinson's disease scales to change over time. Movement Disorders, 2009, 24, 813-818.	3.9	62
178	Neuropsychiatric symptoms in Parkinson's disease. Movement Disorders, 2009, 24, 2175-2186.	3.9	471
179	Opinions and clinical practices related to diagnosing and managing patients with psychogenic movement disorders: An international survey of movement disorder society members. Movement Disorders, 2009, 24, 1366-1374.	3.9	138
180	Myoclonus in complex regional pain syndrome. Movement Disorders, 2009, 24, 314-316.	3.9	22

#	Article	IF	CITATIONS
181	The prognosis of fixed dystonia: A follow-up study. Parkinsonism and Related Disorders, 2009, 15, 592-597.	2.2	71
182	Dopamine dysregulation syndrome, impulse control disorders and punding after deep brain stimulation surgery for Parkinson's disease. Journal of Clinical Neuroscience, 2009, 16, 1148-1152.	1.5	220
183	Streptococcal infection, Tourette syndrome, and OCD. Neurology, 2009, 73, 1256-1263.	1.1	94
184	Depression, anxiety and apathy in Parkinsonâ \in ${}^{\mathrm{MS}}$ s disease. , 2009, , 107-120.		1
185	Cortical excitability is abnormal in patients with the "fixed dystonia―syndrome. Movement Disorders, 2008, 23, 646-652.	3.9	111
186	Survival in multiple system atrophy. Movement Disorders, 2008, 23, 294-296.	3.9	112
187	Red flags for multiple system atrophy. Movement Disorders, 2008, 23, 1093-1099.	3.9	215
188	Reversible "applause sign―secondary to diffuse large B cell lymphoma. Movement Disorders, 2008, 23, 2426-2428.	3.9	10
189	Movement Disorder Societyâ€sponsored revision of the Unified Parkinson's Disease Rating Scale (MDSâ€UPDRS): Scale presentation and clinimetric testing results. Movement Disorders, 2008, 23, 2129-2170.	3.9	4,796
190	Are patients with somatization disorder highly suggestible?. Acta Psychiatrica Scandinavica, 2008, 117, 232-235.	4.5	8
191	A questionnaire-based (UM-PDHQ) study of hallucinations in Parkinson's disease. BMC Neurology, 2008, 8, 21.	1.8	80
192	Impact of Newer Pharmacological Treatments on Quality of Life in Patients with Parkinson???s Disease. CNS Drugs, 2008, 22, 563-586.	5.9	79
193	Unified Parkinson's Disease Rating Scale (UPDRS) part I as a screening and diagnostic instrument for apathy in patients with Parkinson's disease. Parkinsonism and Related Disorders, 2008, 14, 586-587.	2.2	9
194	The Gilles de la Tourette Syndrome–Quality of Life Scale (GTS-QOL). Neurology, 2008, 71, 1410-1416.	1.1	204
195	Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD. Neurology, 2008, 71, 474-480.	1.1	246
196	Quantifying the impact of dyskinesias in PD. Neurology, 2007, 69, 555-563.	1.1	40
197	Estimated life expectancy of Parkinson's patients compared with the UK population. Journal of Neurology, Neurosurgery and Psychiatry, 2007, 78, 1304-1309.	1.9	121
198	Testing the validity of the PDQ-39 in patients with MSA. Parkinsonism and Related Disorders, 2007, 13, 152-156.	2.2	5

#	Article	IF	CITATIONS
199	1.179 A rating instrument for hallucinations in Parkinson's disease: The University of Miami Hallucinations Questionnaire (UMHQ.v2). Parkinsonism and Related Disorders, 2007, 13, S54.	2.2	0
200	Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. Movement Disorders, 2007, 22, 41-47.	3.9	1,097
201	Depression rating scales in Parkinson's disease: Critique and recommendations. Movement Disorders, 2007, 22, 1077-1092.	3.9	583
202	Rate of clinical progression in Parkinson's disease. A prospective study. Movement Disorders, 2007, 22, 938-945.	3.9	129
203	Pathological gambling in Parkinson's disease: Risk factors and differences from dopamine dysregulation. An analysis of published case series. Movement Disorders, 2007, 22, 1757-1763.	3.9	246
204	Measuring healthâ€related quality of life in MSA: The MSAâ€QoL. Movement Disorders, 2007, 22, 2332-2338.	3.9	49
205	Progression of dysautonomia in multiple system atrophy: a prospective study of self-perceived impairment. European Journal of Neurology, 2007, 14, 66-72.	3.3	37
206	TOURETTE'S SYNDROME, TICS AND OBSESSIVE-COMPULSIVE DISORDERS. , 2007, , 214-221.		0
207	Quality of life and depression in Parkinson's disease. Journal of the Neurological Sciences, 2006, 248, 151-157.	0.6	320
208	Caregiver-burden in parkinson's disease is closely associated with psychiatric symptoms, falls, and disability. Parkinsonism and Related Disorders, 2006, 12, 35-41.	2.2	419
209	Epidemiological, clinical, and genetic characteristics of early-onset parkinsonism. Lancet Neurology, The, 2006, 5, 355-363.	10.2	324
210	Healthâ€related quality of life in multiple system atrophy. Movement Disorders, 2006, 21, 809-815.	3.9	102
211	Minimal clinically important change on the unified Parkinson's disease rating scale. Movement Disorders, 2006, 21, 1200-1207.	3.9	253
212	Time of loss of employment in Parkinson's disease. Movement Disorders, 2006, 21, 1839-1843.	3.9	61
213	Measuring quality of life in PSP. Neurology, 2006, 67, 39-44.	1.1	61
214	Psychogenic Dystonia. Medical Psychiatry, 2006, , 277-288.	0.2	0
215	Psychogenic movement disorders. Current Opinion in Neurology, 2005, 18, 399-404.	3.6	46
216	Entacapone in the treatment of Parkinson's disease. Lancet Neurology, The, 2005, 4, 366-370.	10.2	96

#	Article	IF	CITATIONS
217	Depressive symptoms and life satisfaction in patients with multiple system atrophy. Movement Disorders, 2005, 20, 951-957.	3.9	98
218	The European Multiple System Atrophy-Study Group (EMSA-SG). Journal of Neural Transmission, 2005, 112, 1677-1686.	2.8	75
219	Dissociation, Childhood Interpersonal Trauma, and Family Functioning in Patients With Somatization Disorder. American Journal of Psychiatry, 2005, 162, 899-905.	7.2	158
220	Driving in Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2005, 76, 159-159.	1.9	9
221	Measuring health-related quality of life in patients with progressive supranuclear palsy. Neurocase, 2005, 11, 246-249.	0.6	4
222	Reliability of self-reported diagnoses in patients with neurologically unexplained symptoms. Journal of Neurology, Neurosurgery and Psychiatry, 2004, 75, 608-611.	1.9	39
223	Psychiatric aspects of Parkinson?s disease. Journal of Neurology, 2004, 251, 795-804.	3.6	162
224	Occurrence of atypical parkinsonism in Indians and Caucasians. Acta Neurologica Scandinavica, 2004, 109, 155-156.	2.1	1
225	Patterns of EMG-EMG coherence in limb dystonia. Movement Disorders, 2004, 19, 758-769.	3.9	60
226	The syndrome of fixed dystonia: an evaluation of 103 patients. Brain, 2004, 127, 2360-2372.	7.6	338
227	Development of a measure of the impact of chronic parental illness on adolescent and adult children. The Parental Illness Impact Scale (Parkinson's disease). Parkinsonism and Related Disorders, 2004, 10, 399-405.	2.2	19
228	Impact of Parkinson's disease on patients' adolescent and adult children. Parkinsonism and Related Disorders, 2004, 10, 391-397.	2.2	36
229	Anti-basal ganglia antibodies in patients with atypical dystonia and tics. Neurology, 2004, 63, 156-158.	1.1	36
230	Quality of life in patients with orthostatic tremor. Journal of Neurology, 2003, 250, 212-215.	3.6	35
231	Young- versus older-onset Parkinson's disease: Impact of disease and psychosocial consequences. Movement Disorders, 2003, 18, 1250-1256.	3.9	234
232	Healthâ€related quality of life in patients with progressive supranuclear palsy. Movement Disorders, 2003, 18, 1464-1469.	3.9	68
233	Sweating dysfunction in Parkinson's disease. Movement Disorders, 2003, 18, 1459-1463.	3.9	146
234	Parkin disease: a phenotypic study of a large case series. Brain, 2003, 126, 1279-1292.	7.6	427

#	Article	IF	CITATIONS
235	How valid is the clinical diagnosis of Parkinson's disease in the community?. Journal of Neurology, Neurosurgery and Psychiatry, 2002, 73, 529-534.	1.9	237
236	Novel three-stage ascertainment method. Neurology, 2002, 58, 1820-1825.	1.1	53
237	Quality of life in stiff person syndrome. Movement Disorders, 2002, 17, 1064-1067.	3.9	13
238	How common are complications of Parkinson's disease?. Journal of Neurology, 2002, 249, 419-423.	3.6	135
239	Ropinirole for the treatment of tremor in early Parkinson's disease. European Journal of Neurology, 2002, 9, 253-257.	3.3	43
240	Effect of ApoE and tau on age of onset of progressive supranuclear palsy and multiple system atrophy. Neuroscience Letters, 2001, 312, 118-120.	2.1	26
241	What contributes to depression in Parkinson's disease?. Psychological Medicine, 2001, 31, 65-73.	4.5	209
242	Poetic talent unmasked by treatment of Parkinson's disease. Movement Disorders, 2001, 16, 1175-1176.	3.9	69
243	Arm tremor in cervical dystonia differs from essential tremor and can be classified by onset age and spread of symptoms. Brain, 2001, 124, 1765-1776.	7.6	95
244	Firing patterns of pallidal cells in Parkinsonian patients correlate with their pre-pallidotomy clinical scores. NeuroReport, 2000, 11, 3413-3418.	1.2	21
245	Health-related quality of life following bilateral intrastriatal transplantation in Parkinson's disease. Movement Disorders, 2000, 15, 224-229.	3.9	47
246	Benign hereditary chorea?Entity or syndrome?. Movement Disorders, 2000, 15, 280-288.	3.9	80
247	How does Parkinson's disease affect quality of life? A comparison with quality of life in the general population. Movement Disorders, 2000, 15, 1112-1118.	3.9	438
248	Essential tremor: an overdiagnosed condition?. Journal of Neurology, 2000, 247, 955-959.	3.6	201
249	What contributes to quality of life in patients with Parkinson's disease?. Journal of Neurology, Neurosurgery and Psychiatry, 2000, 69, 308-312.	1.9	1,092
250	Cross sectional prevalence survey of idiopathic Parkinson's disease and parkinsonism in London. BMJ: British Medical Journal, 2000, 321, 21-22.	2.3	211
251	Low-dose olanzapine for levodopa induced dyskinesias. Neurology, 2000, 55, 795-799.	1.1	72
252	Multiple system atrophy/progressive supranuclear palsy: α-Synuclein, synphilin, tau, and <i>APOE</i> . Neurology, 2000, 55, 1918-1920.	1.1	82

#	Article	IF	CITATIONS
253	Differentiation of atypical parkinsonian syndromes with routine MRI. Neurology, 2000, 54, 697-697.	1.1	401
254	Bilateral caudate and putamen grafts of embryonic mesencephalic tissue treated with lazaroids in Parkinson's disease. Brain, 2000, 123, 1380-1390.	7.6	266
255	The EQ-5Da generic quality of life measureis a useful instrument to measure quality of life in patients with Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2000, 69, 67-73.	1.9	279
256	Relevance of PSP and MSA to clinical practice. Lancet, The, 2000, 355, 754-755.	13.7	2
257	Dyskinesias and motor fluctuations in Parkinson's disease. Brain, 2000, 123, 2297-2305.	7.6	547
258	Sequential bilateral transplantation in Parkinson's disease: Effects of the second graft. Brain, 1999, 122, 1121-1132.	7.6	241
259	Unilateral pallidotomy for Parkinson's disease: results after more than 1 year. Journal of Neurology, Neurosurgery and Psychiatry, 1999, 67, 511-517.	1.9	28
260	Reduction of parkinsonian signs in patients with Parkinson's disease by dopaminergic versus anticholinergic single-dose challenges. Movement Disorders, 1999, 14, 252-255.	3.9	72
261	Atypical and typical cranial dystonia following dental procedures. Movement Disorders, 1999, 14, 492-496.	3.9	103
262	An unusual jaw tremor with characteristics of primary orthostatic tremor. Movement Disorders, 1999, 14, 528-530.	3.9	23
263	The dancing larynx?a variant of palatal tremor?. Movement Disorders, 1999, 14, 882-883.	3.9	6
264	Overdiagnosis of essential tremor. Lancet, The, 1999, 353, 1498-1499.	13.7	24
265	Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study. Lancet, The, 1999, 354, 1771-1775.	13.7	573
266	Olivopontocerebellar atrophy and multiple system atrophy: Clinical follow-up of 10 patients studied with PET. Annals of Neurology, 1998, 44, 151-152.	5.3	3
267	Youngâ€onset Parkinson's disease revisited—clinical features, natural history, and mortality. Movement Disorders, 1998, 13, 885-894.	3.9	286
268	Huntington's disease and other choreas. Journal of Neurology, 1998, 245, 709-716.	3.6	87
269	Clinical usefulness of magnetic resonance imaging in multiple system atrophy. Journal of Neurology, Neurosurgery and Psychiatry, 1998, 65, 65-71.	1.9	236
270	A study of medial pallidotomy for Parkinson's disease: clinical outcome, MRI location and complications. Brain, 1998, 121, 59-75.	7.6	120

#	Article	IF	CITATIONS
271	The safety of ropinirole, a selective nonergoline dopamine agonist, in patients with Parkinson's disease. Clinical Neuropharmacology, 1998, 21, 169-75.	0.7	27
272	Directional bias of initial visual exploration A symptom of neglect in Parkinson's disease. Brain, 1996, 119, 79-87.	7.6	60
273	Iodine-123-iodo-lisuride SPECT in Parkinson's disease. Journal of Nuclear Medicine, 1996, 37, 22-5.	5.0	9
274	Measuring quality of life in multiple system atrophy. , 0, , 60-70.		0